<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083980</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT000150-01A1</org_study_id>
    <nct_id>NCT00083980</nct_id>
  </id_info>
  <brief_title>Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)</brief_title>
  <official_title>KAVA KAVA in Generalized Anxiety: A Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the herbal medicine
      kava kava for the treatment of generalized anxiety disorder (GAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kava kava (KAV) is a plant-derived treatment widely used in Europe to treat anxiety
      disorders. Several studies suggest that KAV may be effective in reducing anxiety symptoms;
      however, trial data are limited. This study will compare KAV, the drug venlafaxine-XR (VEN),
      and placebo for the treatment of GAD.

      This study will last 10 weeks. Participants will be randomly assigned to receive KAV, VEN, or
      placebo for 8 weeks. Participants will then undergo a 1-week tapering of their medication
      followed by an additional week of observation. Self-report scales and questionnaires will be
      used to assess the anxiety, depression, and functional impairment of participants. Side
      effects, vital signs, and laboratory measures will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    European reports of liver toxicity from kava meant that the study had to stop
  </why_stopped>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Anxiety Scale</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>active antidepressant drug comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venlafaxine ER</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal treatment kava</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kava</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine ER</intervention_name>
    <description>75 to 225 mg daily</description>
    <arm_group_label>active antidepressant drug comparator</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Upto 3 per day for venlafainxe and 4 per day for kava placebos.</description>
    <arm_group_label>active antidepressant drug comparator</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_label>Herbal treatment kava</arm_group_label>
    <other_name>No brand name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kava</intervention_name>
    <description>140 to 280 mg per day</description>
    <arm_group_label>Herbal treatment kava</arm_group_label>
    <other_name>No brand name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of generalized anxiety disorder (GAD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2004</study_first_submitted>
  <study_first_submitted_qc>June 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2004</study_first_posted>
  <last_update_submitted>October 18, 2012</last_update_submitted>
  <last_update_submitted_qc>October 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kava</keyword>
  <keyword>Complementary Therapies</keyword>
  <keyword>Medicine, Herbal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

